Background-Faecal concentrations of the protein calprotectin have been foun
d to be elevated in patients with colorectal neoplasia, suggesting that it
might be used as a screening tool for colorectal cancer as well as adenomas
.
Aims-To measure the sensitivity and specificity of faecal calprotectin for
the detection of adenomas in high risk individuals undergoing colonoscopy.
Also, to investigate between and within stool variability of calprotectin c
oncentrations.
Subjects-A total of 814 patients planned for colonoscopy were included for
the following indications: positive faecal occult blood test, 25; neoplasia
surveillance, 605; newly detected polyp, 130; and family risk, 54.
Methods-Two faecal samples from each of two stools were analysed using the
PhiCal ELISA test device (Nycomed Pharma AS).
Results-Adenoma patients had significantly higher calprotectin levels than
normal subjects (median 9.1 (95% confidence interval 7.5-10.1) v 6.6 (5.6-7
.4)mg/l). There was no significant decrease in calprotectin levels after po
lypectomy. Levels in cancer patients were significantly higher than those i
n all other subgroups (median 17.6 mg/l (11.5-31.0)). With a cut off limit
of 10 mg/l, the sensitivity for cancer was 74% and for adenoma 43%. Corresp
onding specificity values were 64% for no cancer and 67% for no neoplasia (
cancer+adenoma). Specificity varied from 71% for one stool sample to 63% fo
r four samples. Stool variability was small, suggesting that two spots from
one stool were as discriminative as two spots from each of two stools.
Conclusions-The sensitivity and specificity of faecal calprotectin levels a
s a marker for colorectal adenoma and carcinoma justifies its use in high r
isk groups, but specificity is too low for screening of average risk person
s. Lack of a decrease in levels after polypectomy may be due to a more wide
spread leucocyte migration into the intestinal lumen than that at the polyp
site, and needs further investigation.